Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 12-week, randomised, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 dose levels to patients with Chronic Obstructive Pulmonary Disease (COPD) on treatment with tiotropium
To evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR-H065522XX) given intravenously (infusion for 15 or 30 minutes) to patients for conversion of atrial fibrillation
To study the efficacy of iv AZD7009 in all treatment groups versus placebo, in conversion of AF. The primary outcome variable for the evaluation of this objective is: -the proportion of patients tha...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Randomised, Double-Blind, 52-week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretion in Hypercholesterolaemic Non-Diabetic Patients with Moderate Proteinuria PLANET II: Prospective evaLuation of proteinuriA and reNal function in non-diabETic patients with progressive renal disease
The primary objective of this study is to evaluate the effects of rosuvastatin and atorvastatin on urinary protein excretion by evaluation of the change in urinary protein/creatinine ratio from baseli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
AstraZeneca
MAJ Il y a 4 ans
Étude POTOMAC : étude de phase 3 randomisée comparant l’efficacité du bilié de Calmette et Guérin (BCG) associé au durvalumab en comparaison au BCG seul chez des patients naïf du BCG et ayant un cancer de la vessie non infiltrant le muscle.
La vessie sert de réservoir à l’urine qui vient des reins et est ensuite éliminée en urinant. Un cancer de la vessie est une maladie des cellules qui tapissent cet organe. Une cellule initialement nor...
Pays
France
Organes
Vessie
Spécialités
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 52-week International, Phase 3bTrial with a Blinded 104-week Long - term Extension Period to Evaluate Saxagliptin Co-administered with Dapagliflozin in combination with Metformin Compared to Glimepiride in Combination with Metformin in Patients with Type 2 Diabetes
To compare the mean change from baseline in HbA1c achieved with saxagliptin, in co-administration with dapagliflozin, added to current background therapy with metformin, compared to glimepiride added ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN (SATURN): A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease
The primary objective of this study is to compare the effects of rosuvastatin 40mg with atorvastatin 80mg on the percent atheroma volume (PAV) of a coronary artery as measured by intravascular ultraso...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
To investigate the tolerability and safety of inhaled AZD4818 delivered via a dry powder inhaler, Turbuhaler®, in COPD patients by assessment of: . incidence and nature of adverse events (AE) . Electr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden
MAJ Il y a 4 ans
A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD (Chronic obstructive pulmonary disease) symptoms including cough when administered to patients with COPD
1. To assess the effect of aclidinium bromide 400 µg administered twice a day on COPD symptoms including cough in patients with moderate COPD compared to placebo. 2. To assess the effects of aclidin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients with Moderate to Severe COPD
To investigate the tolerability and safety of AZD2423 in patients with COPD
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
An Open Label, Single Arm, Multicentre Study of Lynparza (Olaparib) Capsules in Relapsed BRCA Mutated Ovarian Cancer Patients (ORZORA)
To assess the real world clinical effectiveness of olaparib maintenance monotherapy by investigator assessed progression free survival (PFS) according to modified Response Evaluation Criteria In Solid...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
8
9
10
11
12
13
14
15
16
17
Suivant